WFRF:(Flandin G)
Search: WFRF:(Flandin G) > Pathologic Response...
- 4 of 4
- Previous record
- Next record
- To hitlist
Pathologic Response to Neoadjuvant Sequential Chemoradiation Therapy in Locally Advanced Breast Cancer: Preliminary, Translational Results from the French Neo-APBI-01 Trial
- To, NH (author)
- Gabelle-Flandin, I (author)
- Luong, TMH (author)
- show more...
- Loganadane, G (author)
- Ouidir, N (author)
- Boukhobza, C (author)
- Grellier, N (author)
- Verry, C (author)
- Thiolat, A (author)
- Cohen, JL (author)
- Radosevic-Robin, N (author)
- Belkacemi, Y (author)
- show less...
- 2023-03-29
- 2023
- English.
- In: Cancers. - : MDPI AG. - 2072-6694. ; 15:7
- Journal article (peer-reviewed)
Abstract
Subject headings
Close
- Background: Radiation therapy (RT), a novel approach to boost the anticancer immune response, has been progressively evaluated in the neoadjuvant setting in breast cancer (BC). Purpose: We aimed to evaluate immunity-related indicators of response to neoadjuvant chemoradiation therapy (NACRT) in BC for better treatment personalization. Patients and Methods: We analyzed data of the first 42 patients included in the randomized phase 2 Neo-APBI-01 trial comparing standard neoadjuvant chemotherapy (NACT) and NACRT regimen in locally advanced triple-negative (TN) and luminal B (LB) subtype BC. Clinicopathological parameters, blood counts and the derived parameters, total tumor-infiltrating lymphocytes (TILs) and their subpopulation, as well as TP53 mutation status, were assessed as predictors of response. Results: Twenty-one patients were equally assigned to each group. The pathologic complete response (pCR) was 33% and 38% in the NACT and NACRT groups, respectively, with a dose-response effect. Only one LB tumor reached pCR after NACRT. Numerous parameters associated with response were identified, which differed according to the assigned treatment. In the NACRT group, baseline hemoglobin of ≥13 g/dL and body mass index of <26 were strongly associated with pCR. Higher baseline neutrophils-to-lymphocytes ratio, total TILs, and T-effector cell counts were favorable for pCR. Conclusion: This preliminary analysis identified LB and low-TIL tumors as poor responders to the NACRT protocol, which delivered RT after several cycles of chemotherapy. These findings will allow for amending the selection of patients for the trial and help better design future trials of NACRT in BC.
Publication and Content Type
- ref (subject category)
- art (subject category)
- 4 of 4
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- To, NH
- Gabelle-Flandin, ...
- Luong, TMH
- Loganadane, G
- Ouidir, N
- Boukhobza, C
- show more...
- Grellier, N
- Verry, C
- Thiolat, A
- Cohen, JL
- Radosevic-Robin, ...
- Belkacemi, Y
- show less...
- Articles in the publication
- Cancers
- By the university
- Karolinska Institutet
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
